Empty Iv Bag MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Chamber TypeBy CapacityBy Distribution Channel

An empty IV bag is a flexible plastic container, made from PVC or non-PVC polymer film, sold unfilled for later fill-finish with intravenous fluids, injectable medications, or parenteral nutrition solutions. Buyers are pharmaceutical manufacturers, contract fill-finish operators, compounding pharmacies, and hospitals and clinics that prepare or receive sterile fluid products. Bags vary by chamber configuration, fill volume, and film material to suit different clinical delivery and drug-compatibility needs.

USD 2.85 billion of revenue was recorded in the global empty iv bag market in 2025. By 2034 the figure reaches USD 5.37 billion, a compound annual growth rate of 7.37% through the forecast period, along a series that runs USD 2.13 billion in 2020, USD 2.68 billion in 2024, USD 3.04 billion in 2026 and USD 4.03 billion in 2030.

Composition changes more than the total does. Non-PVC Empty IV Bags, at 9.81%, outgrows PVC Empty IV Bags at 5.48%, and its share moves from 38.9% to 48%. PVC Empty IV Bags stays the largest line throughout, at USD 1.74 billion in 2025 and USD 2.79 billion in 2034. Share moves toward Non-PVC Empty IV Bags and away from PVC Empty IV Bags, though no line shrinks in revenue terms.

The application split puts Hospital first, at USD 2.22 billion and 77.9% of revenue in 2025, rising to USD 3.97 billion and 73.9% in 2034. Clinic grows faster at 9.28% against 6.68%, moving from 22.1% of revenue to 26.1% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

The regional order runs from North America at 34% of 2025 revenue down to Middle East and Africa at 5%. North America is worth USD 0.97 billion in 2025 and USD 1.66 billion in 2034; Asia Pacific, second at 28%, moves from USD 0.8 billion to USD 1.72 billion. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• A forecast-period rate of 7.37% takes the market from USD 2.85 billion in 2025 to USD 5.37 billion in 2034, against 6% recorded over the 2020-2025 historical period.
• PVC Empty IV Bags is the largest type line at USD 1.74 billion in 2025, a 61.1% share, reaching USD 2.79 billion and 52% of revenue by 2034.
• Non-PVC Empty IV Bags is the fastest-growing line at 9.81%, lifting its share from 38.9% in 2025 to 48% in 2034 and its revenue from USD 1.11 billion to USD 2.58 billion.
• The bull case puts 2034 revenue at USD 6.01 billion and the bear case at USD 4.83 billion, either side of the USD 5.37 billion base case, each with its own stated assumption in the full report.
• The largest region is North America, generating USD 0.97 billion in 2025 (34% of the global total) and USD 1.66 billion by 2034, ahead of Asia Pacific at 28%.
• The United States accounts for 84.5% of North America in the base year, worth USD 0.82 billion in 2025 and reaching USD 1.39 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 7.37% compounding underneath both.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Non-PVC Empty IV Bags outpaces PVC Empty IV Bags. Non-PVC Empty IV Bags grows at 9.81% across 2026-2034 against 5.48% for PVC Empty IV Bags, the widest spread on the type axis. Non-PVC Empty IV Bags takes its share of revenue from 38.9% to 48% while PVC Empty IV Bags gives up ground, from 61.1% to 52%. Revenue rises on both sides; USD 1.11 billion to USD 2.58 billion and USD 1.74 billion to USD 2.79 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

The regional balance moves. Asia Pacific moves from 28% of revenue in 2025 to 32% in 2034, worth USD 0.8 billion rising to USD 1.72 billion; Latin America moves from 7% of revenue in 2025 to 7.5% in 2034, worth USD 0.2 billion rising to USD 0.4 billion; Middle East and Africa moves from 5% of revenue in 2025 to 5.5% in 2034, worth USD 0.14 billion rising to USD 0.3 billion. Against that, North America at 34% moving to 31%, Europe at 26% moving to 24%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Growth compounds at 7.37% without a step change. Reading the series: USD 2.13 billion in 2020, USD 2.68 billion in 2024, USD 2.85 billion in 2025, USD 3.04 billion in 2026, USD 4.03 billion in 2030 and USD 5.37 billion in 2034. No year breaks the trajectory, and the 7.37% forecast rate compares with 6% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

The fastest line decides the blended rate

Growth in the global empty iv bag market comes from three measurable sources over 2026-2034: the market's own compounding at 7.37%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

What the bull case turns on

The total depends on a single line

USD 0.97 billion of 2025 revenue is generated in North America, 34% of the global empty iv bag market rising to USD 1.66 billion in 2034. It is a leading region on this axis, first by revenue throughout the period.

31% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The type mix reported at global level applies here, with PVC Empty IV Bags the largest line at 61.1% of 2025 revenue and Non-PVC Empty IV Bags the fastest-growing at 9.81%. North America is reported axis by axis and country by country in the full study.

The largest single market in North America is the United States, at USD 0.82 billion in 2025 and USD 1.39 billion in 2034. Because it is 84.5% of the region in the base year, North America's totals move with this one country instead of a spread of them. Set against USD 0.97 billion and USD 1.66 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

the United States buys along the same lines as the market globally; PVC Empty IV Bags first at 61.1% of 2025 revenue and 52% in 2034, Non-PVC Empty IV Bags fastest at 9.81% on a share moving from 38.9% to 48%. Since 84.5% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for the United States appears on its own in the full report.

The Food and Drug Administration regulates empty intravenous bags as medical devices under its device classification framework, since the container is intended to hold and deliver a sterile fluid to a patient. A manufacturer must clear the product through the appropriate premarket pathway before marketing it, typically by demonstrating equivalence to a legally marketed predicate container. Facilities producing these bags must operate under the Quality System Regulation, covering design controls, sterilization validation, and material biocompatibility testing. Labeling must identify the manufacturer, lot, sterility status, and intended use, and materials are commonly tested against compendial standards set by the United States Pharmacopeia for container closure integrity and leachable substances.

The suppliers tracked in this study (Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others) compete in the United States across the type lines above. The commercially relevant division is 61.1% of 2025 revenue in PVC Empty IV Bags, where the volume is, against 9.81% growth in Non-PVC Empty IV Bags, where share moves. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 0.15 billion in 2025, rising to USD 0.27 billion by 2034; 5.3% of global revenue and 15.5% of North America. It is reported separately from the United States across every segmentation axis in the full report.

26% of the global empty iv bag market sits in Europe in 2025, worth USD 0.74 billion and reaches USD 1.29 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

By 2034 the share stands at 24%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The type mix reported at global level applies here, with PVC Empty IV Bags the largest line at 61.1% of 2025 revenue and Non-PVC Empty IV Bags the fastest-growing at 9.81%. Europe is reported axis by axis and country by country in the full study.

29.7% of Europe's base-year revenue comes from Germany; USD 0.22 billion, rising to USD 0.37 billion by 2034. It accounts for 29.7% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.74 billion to USD 1.29 billion over the same period, and this is the market carrying the country-level detail in the full report.

The type pattern in Germany is the global one: 61.1% of 2025 revenue in PVC Empty IV Bags, 52% by 2034, against 9.81% growth in Non-PVC Empty IV Bags taking it from 38.9% to 48%. Its 29.7% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.

Empty intravenous bags sold in Germany fall under the European Union's Medical Device Regulation, administered domestically through the national competent authority alongside notified bodies that assess conformity before a product carries the CE mark. As a sterile fluid-path container, the bag is classified according to the duration and route of patient contact, and the manufacturer must compile technical documentation covering material safety, sterilization method, and clinical evaluation. A quality management system certified to the relevant ISO standard for medical device manufacturing is expected, and labelling must meet the regulation's requirements for language, traceability through a unique device identifier, and instructions for safe use. Post-market surveillance obligations continue after the product reaches the market.

In Germany the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. Volume sits in PVC Empty IV Bags at 61.1% of 2025 revenue; movement sits in Non-PVC Empty IV Bags at 9.81% growth.

The United Kingdom is sized at USD 0.16 billion in 2025, rising to USD 0.27 billion by 2034; 5.6% of global revenue and 21.6% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

France is sized at USD 0.13 billion in 2025, rising to USD 0.22 billion by 2034; 4.6% of global revenue and 17.6% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

28% of the global empty iv bag market sits in Asia Pacific in 2025, worth USD 0.8 billion with USD 1.72 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 32% by 2034, on growth above the market's own 7.37%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 61.1% of 2025 revenue in PVC Empty IV Bags, fastest growth of 9.81% in Non-PVC Empty IV Bags. The full report breaks Asia Pacific out along every axis and by country.

The largest single market in Asia Pacific is China, at USD 0.32 billion in 2025 and USD 0.71 billion in 2034. It accounts for 40% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.8 billion to USD 1.72 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is PVC Empty IV Bags at 61.1% of 2025 revenue, easing to 52% by 2034, and the fastest is Non-PVC Empty IV Bags at 9.81%, from 38.9% to 48%. Its 40% weight in Asia Pacific means those movements carry straight into the regional totals. Per-type revenue for China appears on its own in the full report.

In China, empty intravenous bags are regulated as medical devices by the National Medical Products Administration, which assigns products to a risk-based classification before any registration application can proceed. A domestic or foreign manufacturer must obtain a medical device registration certificate, supported by testing reports on material composition, sterility, and container integrity conducted at recognized laboratories, along with a quality management system audit. Labelling and Chinese-language instructions must disclose the manufacturer, intended use, and storage conditions, and imported products additionally require a local agent responsible for post-market obligations. Standards conformity is generally assessed against national pharmacopoeia and medical device standards rather than accepting foreign certification alone.

In China the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. The commercially relevant division is 61.1% of 2025 revenue in PVC Empty IV Bags, where the volume is, against 9.81% growth in Non-PVC Empty IV Bags, where share moves.

6.3% of global revenue is generated in India; USD 0.18 billion in 2025, reaching USD 0.4 billion in 2034, and 22.5% of Asia Pacific.

Japan is sized at USD 0.14 billion in 2025, rising to USD 0.28 billion by 2034; 4.9% of global revenue and 17.5% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Latin America holds 7% of the global empty iv bag market in 2025, worth USD 0.2 billion with USD 0.4 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 7.5%, on growth above the market's own 7.37%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

PVC Empty IV Bags leads here as it does globally, at 61.1% of 2025 revenue, and Non-PVC Empty IV Bags again grows fastest at 9.81%. Per-axis and per-country detail for Latin America sits in the full report.

55% of Latin America's base-year revenue comes from Brazil; USD 0.11 billion, rising to USD 0.22 billion by 2034. At 55% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 0.2 billion to USD 0.4 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; PVC Empty IV Bags first at 61.1% of 2025 revenue and 52% in 2034, Non-PVC Empty IV Bags fastest at 9.81% on a share moving from 38.9% to 48%. Because the country carries 55% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Brazil carries its own type breakdown in the full report.

Brazil's health regulatory authority, Anvisa, oversees empty intravenous bags as medical devices, placing them within its risk classification system that determines whether a product may be registered through a simplified notification or requires a fuller technical review. Manufacturers must demonstrate compliance with Brazilian good manufacturing practice requirements, which Anvisa verifies either directly or by recognizing certification from other regulatory systems under its reliance pathways. Sterility, material biocompatibility, and container integrity testing must be documented in the registration dossier, and Portuguese-language labelling must state the manufacturer, batch identification, expiry, and storage instructions. A local registration holder based in Brazil is required for any manufacturer without a domestic presence.

In Brazil the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. PVC Empty IV Bags, at 61.1% of 2025 revenue, is where the volume sits, and Non-PVC Empty IV Bags, growing at 9.81%, is where position changes hands over the forecast period.

2.1% of global revenue is generated in Mexico; USD 0.06 billion in 2025, reaching USD 0.12 billion in 2034, and 30% of Latin America.

USD 0.14 billion of 2025 revenue is generated in Middle East and Africa, 5% of the global empty iv bag market rising to USD 0.3 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

By 2034 the share has moved up to 5.5%, so the region grows faster than the market's 7.37% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

PVC Empty IV Bags leads here as it does globally, at 61.1% of 2025 revenue, and Non-PVC Empty IV Bags again grows fastest at 9.81%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

35.7% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.05 billion, rising to USD 0.11 billion by 2034. At 35.7% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 0.14 billion in 2025 and USD 0.3 billion in 2034, it is the country the full report breaks out in detail.

Demand in Saudi Arabia follows the type mix reported at global level: PVC Empty IV Bags is the largest line at 61.1% of 2025 revenue, moving to 52% by 2034, while Non-PVC Empty IV Bags grows fastest at 9.81% and takes its share from 38.9% to 48%. With 35.7% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Saudi Arabia carries its own type breakdown in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates empty intravenous bags under its medical device framework, which follows the classification and conformity assessment principles set out by the International Medical Device Regulators Forum. A manufacturer must register the product through the authority's electronic system and hold a valid marketing authorization before distribution, generally supported by evidence of conformity already granted by a reference regulatory body such as the United States, the European Union, or another recognized jurisdiction. Labelling must appear in Arabic alongside English, identifying the manufacturer, authorized local representative, sterility status, and intended use. Ongoing compliance includes adverse event reporting and maintenance of authorization through periodic renewal.

In Saudi Arabia the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. PVC Empty IV Bags, at 61.1% of 2025 revenue, is where the volume sits, and Non-PVC Empty IV Bags, growing at 9.81%, is where position changes hands over the forecast period.

Within Middle East and Africa, South Africa accounts for 28.6% of regional revenue and 1.4% of the global total, worth USD 0.04 billion in 2025 and USD 0.08 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, chamber type, capacity, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.